The week in health tech, explained in plain English.Get the free newsletter →
October 23, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Government

GOP Pushes Fraud Message to Deflect Healthcare Cost Anger

Republicans are putting anti-fraud enforcement at the center of their healthcare pitch heading into the midterms, casting crackdowns on Medicaid and Affordable Care Act spending as a defense of taxpayer money, KFF Health News reports. The strategy arrives as voters express mounting frustration over healthcare affordability, giving the GOP a way to redirect that anger toward "bad actors" rather than premiums and out-of-pocket costs.

Democrats counter that the administration is using fraud claims, with insufficient evidence, to single out blue states and lay groundwork for shrinking programs the party has long wanted to cut. The dispute reflects a deeper fight over the future of Medicaid and the ACA, two programs that cover tens of millions of Americans.

For health systems, insurers, and state agencies, the practical stakes are real. Intensified fraud investigations can translate into audits, funding uncertainty, and tighter eligibility rules, all of which ripple into coverage, reimbursement, and administrative burden well before any votes are cast.

More in Government

Government

Feds Launch False Claims Act Self-Disclosure Pilot

HHS and the DOJ Civil Division have launched a six-month pilot letting healthcare companies self-report potential civil False Claims Act violations and settle through a coordinated civil release.

Why it matters: The pilot reshapes how hospitals and healthcare firms weigh self-reporting against federal fraud enforcement, with real consequences for compliance strategy.

Government

CMS Targets PBM Fees and MA Directory Accuracy in New Rule

CMS proposed a rule on Oct. 16 that would publicly score Medicare Advantage provider directories and mandate flat-fee payment structures for PBMs, with comments due Dec. 15.

Why it matters: Public directory scores and flat PBM fees would reshape how Medicare Advantage plans and drug middlemen operate and get paid.

Government

Pennsylvania Sues Insulin Makers and PBMs Over Pricing

Pennsylvania's attorney general sued three insulin makers and several PBMs, alleging they colluded to manipulate insulin prices and raise patient costs.

Why it matters: The case adds to mounting legal pressure on insulin pricing and PBM rebate practices that determine what diabetic patients pay at the pharmacy.